Myotonic dystrophy types 1 and 2

Tetsuo Ashizawa, Partha Sarkar

Research output: Book/ReportBook

51 Citations (Scopus)

Abstract

Myotonic dystrophies (dystrophia myotonica, or DM) are inherited disorders characterized by myotonia and progressive muscle degeneration, which are variably associated with a multisystemic phenotype. To date, two types of myotonic dystrophy, type 1 (DM1) and type 2 (DM2), are known to exist; both are autosomal dominant disorders caused by expansion of an untranslated short tandem repeat DNA sequence (CTG)n and (CCTG)n, respectively. These expanded repeats in DM1 and DM2 show different patterns of repeat-size instability. Phenotypes of DM1 and DM2 are similar but there are some important differences, most conspicuously in the severity of the disease (including the presence or absence of the congenital form), muscles primarily affected (distal versus proximal), involved muscle fiber types (type 1 versus type 2 fibers), and some associated multisystemic phenotypes. The pathogenic mechanism of DM1 and DM2 is thought to be mediated by the mutant RNA transcripts containing expanded CUG and CCUG repeats. Strong evidence supports the hypothesis that sequestration of muscle-blind like (MBNL) proteins by these expanded repeats leads to misregulated splicing of many gene transcripts in corroboration with the raised level of CUG-binding protein 1. However, additional mechanisms, such as changes in the chromatin structure involving CTCN-binding site and gene expression dysregulations, are emerging. Although treatment of DM1 and DM2 is currently limited to supportive therapies, new therapeutic approaches based on pathogenic mechanisms may become feasible in the near future.

Original languageEnglish (US)
PublisherUnknown Publisher
Number of pages45
Volume101
DOIs
StatePublished - 2011

Publication series

NameHandbook of Clinical Neurology
Volume101
ISSN (Print)00729752

Fingerprint

Myotonic Dystrophy
Phenotype
Muscles
Slow-Twitch Muscle Fibers
Myotonia
Tandem Repeat Sequences
Microsatellite Repeats
Chromatin
Carrier Proteins
Binding Sites
RNA
Gene Expression
Therapeutics
Genes
Proteins

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Ashizawa, T., & Sarkar, P. (2011). Myotonic dystrophy types 1 and 2. (Handbook of Clinical Neurology; Vol. 101). Unknown Publisher. https://doi.org/10.1016/B978-0-08-045031-5.00015-3

Myotonic dystrophy types 1 and 2. / Ashizawa, Tetsuo; Sarkar, Partha.

Unknown Publisher, 2011. 45 p. (Handbook of Clinical Neurology; Vol. 101).

Research output: Book/ReportBook

Ashizawa, T & Sarkar, P 2011, Myotonic dystrophy types 1 and 2. Handbook of Clinical Neurology, vol. 101, vol. 101, Unknown Publisher. https://doi.org/10.1016/B978-0-08-045031-5.00015-3
Ashizawa T, Sarkar P. Myotonic dystrophy types 1 and 2. Unknown Publisher, 2011. 45 p. (Handbook of Clinical Neurology). https://doi.org/10.1016/B978-0-08-045031-5.00015-3
Ashizawa, Tetsuo ; Sarkar, Partha. / Myotonic dystrophy types 1 and 2. Unknown Publisher, 2011. 45 p. (Handbook of Clinical Neurology).
@book{8b4d6fe873154997b11abc8bc3158c34,
title = "Myotonic dystrophy types 1 and 2",
abstract = "Myotonic dystrophies (dystrophia myotonica, or DM) are inherited disorders characterized by myotonia and progressive muscle degeneration, which are variably associated with a multisystemic phenotype. To date, two types of myotonic dystrophy, type 1 (DM1) and type 2 (DM2), are known to exist; both are autosomal dominant disorders caused by expansion of an untranslated short tandem repeat DNA sequence (CTG)n and (CCTG)n, respectively. These expanded repeats in DM1 and DM2 show different patterns of repeat-size instability. Phenotypes of DM1 and DM2 are similar but there are some important differences, most conspicuously in the severity of the disease (including the presence or absence of the congenital form), muscles primarily affected (distal versus proximal), involved muscle fiber types (type 1 versus type 2 fibers), and some associated multisystemic phenotypes. The pathogenic mechanism of DM1 and DM2 is thought to be mediated by the mutant RNA transcripts containing expanded CUG and CCUG repeats. Strong evidence supports the hypothesis that sequestration of muscle-blind like (MBNL) proteins by these expanded repeats leads to misregulated splicing of many gene transcripts in corroboration with the raised level of CUG-binding protein 1. However, additional mechanisms, such as changes in the chromatin structure involving CTCN-binding site and gene expression dysregulations, are emerging. Although treatment of DM1 and DM2 is currently limited to supportive therapies, new therapeutic approaches based on pathogenic mechanisms may become feasible in the near future.",
author = "Tetsuo Ashizawa and Partha Sarkar",
year = "2011",
doi = "10.1016/B978-0-08-045031-5.00015-3",
language = "English (US)",
volume = "101",
series = "Handbook of Clinical Neurology",
publisher = "Unknown Publisher",

}

TY - BOOK

T1 - Myotonic dystrophy types 1 and 2

AU - Ashizawa, Tetsuo

AU - Sarkar, Partha

PY - 2011

Y1 - 2011

N2 - Myotonic dystrophies (dystrophia myotonica, or DM) are inherited disorders characterized by myotonia and progressive muscle degeneration, which are variably associated with a multisystemic phenotype. To date, two types of myotonic dystrophy, type 1 (DM1) and type 2 (DM2), are known to exist; both are autosomal dominant disorders caused by expansion of an untranslated short tandem repeat DNA sequence (CTG)n and (CCTG)n, respectively. These expanded repeats in DM1 and DM2 show different patterns of repeat-size instability. Phenotypes of DM1 and DM2 are similar but there are some important differences, most conspicuously in the severity of the disease (including the presence or absence of the congenital form), muscles primarily affected (distal versus proximal), involved muscle fiber types (type 1 versus type 2 fibers), and some associated multisystemic phenotypes. The pathogenic mechanism of DM1 and DM2 is thought to be mediated by the mutant RNA transcripts containing expanded CUG and CCUG repeats. Strong evidence supports the hypothesis that sequestration of muscle-blind like (MBNL) proteins by these expanded repeats leads to misregulated splicing of many gene transcripts in corroboration with the raised level of CUG-binding protein 1. However, additional mechanisms, such as changes in the chromatin structure involving CTCN-binding site and gene expression dysregulations, are emerging. Although treatment of DM1 and DM2 is currently limited to supportive therapies, new therapeutic approaches based on pathogenic mechanisms may become feasible in the near future.

AB - Myotonic dystrophies (dystrophia myotonica, or DM) are inherited disorders characterized by myotonia and progressive muscle degeneration, which are variably associated with a multisystemic phenotype. To date, two types of myotonic dystrophy, type 1 (DM1) and type 2 (DM2), are known to exist; both are autosomal dominant disorders caused by expansion of an untranslated short tandem repeat DNA sequence (CTG)n and (CCTG)n, respectively. These expanded repeats in DM1 and DM2 show different patterns of repeat-size instability. Phenotypes of DM1 and DM2 are similar but there are some important differences, most conspicuously in the severity of the disease (including the presence or absence of the congenital form), muscles primarily affected (distal versus proximal), involved muscle fiber types (type 1 versus type 2 fibers), and some associated multisystemic phenotypes. The pathogenic mechanism of DM1 and DM2 is thought to be mediated by the mutant RNA transcripts containing expanded CUG and CCUG repeats. Strong evidence supports the hypothesis that sequestration of muscle-blind like (MBNL) proteins by these expanded repeats leads to misregulated splicing of many gene transcripts in corroboration with the raised level of CUG-binding protein 1. However, additional mechanisms, such as changes in the chromatin structure involving CTCN-binding site and gene expression dysregulations, are emerging. Although treatment of DM1 and DM2 is currently limited to supportive therapies, new therapeutic approaches based on pathogenic mechanisms may become feasible in the near future.

UR - http://www.scopus.com/inward/record.url?scp=79954591424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954591424&partnerID=8YFLogxK

U2 - 10.1016/B978-0-08-045031-5.00015-3

DO - 10.1016/B978-0-08-045031-5.00015-3

M3 - Book

C2 - 21496635

AN - SCOPUS:79954591424

VL - 101

T3 - Handbook of Clinical Neurology

BT - Myotonic dystrophy types 1 and 2

PB - Unknown Publisher

ER -